Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.47 |
| ▸ | RAB9A | P51151 | 5/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2293994 | 0.93 | NPC1 (0.47) | NPC1RAB9ASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL2297504 | 0.88 | FFAR1 (0.48) | NPC1RAB9ASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL2295598 | 0.87 | MEN1 (0.43) | NPC1RAB9ASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL2298688 | 0.86 | NPC1 (0.48) | NPC1RAB9ASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL2294479 | 0.86 | FADS1 (0.46) | NPC1RAB9ASMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL2295055 | 0.85 | KDR (0.47) | NPC1RAB9ASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL2292686 | 0.85 | NPC1 (0.37) | NPC1RAB9ASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL2294478 | 0.84 | NPC1 (0.48) | NPC1RAB9ASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL2295379 | 0.84 | NR1H4 (0.47) | NPC1RAB9AKMT2AMEN1MAPT | |
| SCHEMBL5302849 | 0.83 | KLKB1 (0.45) | SMN1; SMN2KMT2AMEN1HTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003806-B2 | Integrin antagonists useful as anticancer agents | OSI Pharmaceuticals, LLC (US) | 2011-08-23 | — | — | US | claimed |
| EP-1828144-A2 | INTEGRIN ANTAGONISTS USEFUL AS ANTICANCER AGENTS | OSI Pharmaceuticals, Inc. (US) | 2007-09-05 | — | — | EP | claimed |
| US-20060116383-A1 | Integrin antagonists useful as anticancer agents | ALCATEL LUCENT (FR) | 2006-06-01 | — | — | US | claimed |
| WO-2006053342-A2 | INTEGRIN ANTAGONISTS USEFUL AS ANTICANCER AGENTS | OSI PHARMACEUTICALS, INC. (US) | 2006-05-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116383-A1 | Integrin antagonists useful as anticancer agents | ITGB5, ITGA5, ITGB1 | NPC1 2770/4885RAB9A 1893/4885SMN1; SMN2 2159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.